Fast-Acting Human Insulin Analogs: A Promising Innovation in Diabetes Care

Galloway JA Chance RE Insulin agonist therapy: a challenge for the 1990s Clin Therapeutics 1990:12;459-72.

Bliss M. A history of insulin Diabetes Care 1993;16(suppl 3):4-7.

Heinemann L. , Richter B. Clinical pharmacology of human insulin Diabetes Care 1993; 16(suppl 3):90-100.

Galloway JA New directions in drug development : mixtures, analogues, and modeling Diabetes Care 1993;16(suppl 3):16-24.

Stramm LE The role of the pharmaceutical industry in implementing the DCCT recommendations IDF Bull 1994;39(suppl 1):16-20.

Galloway JA , Chance RE , Su KE Human insulin and its modifications In: Reidenberg MM, ed. The clinical pharmacology of biotechnology products. New York: Elsevier Science Publishers, 1991:23-24.

The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications of insulin-dependent diabetes mellitus N Engl J Med 1993;329:977-88.

Zinman B. Insulin regimens and strategies for IDDM Diabetes Care 1993;16(suppl 3): 24-28.

Howey DC , Bowsher RR , Brunelle RL , Woodworth JR [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin Diabetes 1994;43:396-402.

Garg SK , Carmain JA , Braddy KC , Jennings MK , Chase HP Pre-meal insulin analog (Lys-Pro) vs human regular insulin treatment in young subjects with type I diabetes [Abstract] Diabetes 1994;43(suppl 1):162A.

Bcrgenstal R. , Spencer M. , Castle G., et al. Intensive insulin management of type I and type II diabetes: a comparison of [Lys(B28), Pro(B29)]-human insulin and regular human insulin [Abstract] Diabetes 1994;43(suppl 1):157A.